Equities

Innova Captab Ltd

INNOVACAP:NSI

Innova Captab Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)478.80
  • Today's Change9.90 / 2.11%
  • Shares traded67.51k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 15 2024 11:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Innova Captab Ltd is an integrated pharmaceutical company. The Company is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It has presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution and marketing and exports. Its business includes CDMO business, domestic branded generics business, and international branded generic product business. Its CDMO business provides research, product development and manufacturing services. Its branded generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under its own brand names through online and offline channels. Its generic drug products are also available online through various e-commerce pharmacy sites. It has developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals.

  • Revenue in INR (TTM)--
  • Net income in INR--
  • Incorporated2005
  • Employees--
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
INNOVACAP:NSI since
announced
Transaction
value
Sharon Bio-Medicine LtdDeal completed17 May 202317 May 2023Deal completed--23.75m
Data delayed at least 15 minutes, as of May 15 2024 11:25 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Themis Medicare Ltd3.64bn452.86m19.06bn996.0042.16--33.285.244.914.9139.49--------3,655,101.00--9.59--14.9465.5860.1312.4413.15------7.33-10.2110.85-21.9338.1824.51--
Solara Active Pharma Sciences Ltd14.07bn-3.08bn19.68bn2.36k------1.40-85.65-85.65390.73--------5,958,916.00--2.68--4.1040.4744.49-21.884.58---1.67--10.1013.8322.6161.86--26.23--
Amrutanjan Health Care Ltd3.94bn440.09m21.68bn575.0049.59--43.495.4915.1315.13135.41--------6,860,612.00--17.04--21.2249.5154.0811.1613.37--341.76--17.21-6.4611.37-40.7114.7223.8710.64
Suven Life Sciences Ltd116.93m-1.05bn21.86bn132.00--8.10--186.97-4.82-4.820.535912.380.0347--11.17---31.19-46.46-32.37-50.52-----898.63-787.6118.94-849.160.0026---13.64-47.2311.15------
Morepen Laboratories Ltd16.31bn761.19m23.72bn1.65k30.75--22.181.451.511.5132.53--------9,891,111.00--7.39--13.7835.8532.824.675.19--27.34--0.00-8.3618.51-61.965.5011.33--
RPG Life Sciences Limited5.82bn876.60m24.53bn1.17k27.976.5423.424.2153.0153.01351.99226.651.251.8813.45--18.8116.0725.1021.7768.3064.0415.0611.991.50246.840.0029.2713.5012.0129.6051.9828.6046.14
Innova Captab Ltd-100.00bn-100.00bn26.83bn--------------------------------------------------15.72--6.26------
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn27.88bn1.23k--88.17----------12.72------------------------0.8228--0.2681--43.84--77.37------
SeQuent Scientific Ltd13.75bn-1.29bn28.90bn478.00------2.10-5.18-5.1855.33--------28,769,920.00--2.33--3.6742.7842.47-8.972.59---0.3894--17.270.572810.84-395.83--12.88--
Indoco Remedies Ltd17.96bn1.02bn30.47bn6.10k30.24--16.551.7010.9310.93192.26--------2,943,454.00--6.07--8.9069.3965.355.616.30--5.11--14.798.309.81-8.1128.158.2517.61
Supriya Lifescience Ltd5.54bn1.20bn30.81bn392.0025.57--22.775.5614.9714.9768.93--------14,144,410.00--20.77--29.0661.9455.8321.7224.33--63.63--2.02-13.0416.70-40.8159.4185.55--
Dishman Carbogen Amcis Ltd25.80bn-1.54bn31.69bn1.30k----21.501.23-9.84-9.84164.35--------19,919,850.00--0.4699--0.566576.9374.36-5.981.82---0.1245--202.7612.727.32-265.46--21.54--
Gufic BioSciences Ltd7.85bn841.95m32.75bn1.63k37.88--31.054.178.628.6280.38--------4,820,074.00--12.30--23.0851.0844.9110.739.84--8.22--1.39-11.3617.47-16.8437.0686.8214.87
Hikal Ltd17.85bn696.00m35.36bn2.14k50.752.9818.891.985.655.65144.7796.320.73252.663.60--2.865.074.037.5153.7947.223.905.860.87612.650.407716.88-11.792.34-11.20-7.559.720.00
Data as of May 15 2024. Currency figures normalised to Innova Captab Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

14.61%Per cent of shares held by top holders
HolderShares% Held
Kotak Mahindra Asset Management Co. Ltd.as of 30 Apr 20242.29m4.00%
Canara Robeco Asset Management Co. Ltd.as of 30 Apr 20242.11m3.69%
Invesco Asset Management (India) Pvt Ltd.as of 30 Apr 20241.42m2.47%
SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 29 Feb 20241.22m2.13%
WhiteOak Capital Asset Management Ltd.as of 30 Apr 2024732.48k1.28%
Bandhan Asset Management Co. Ltd.as of 30 Apr 2024298.56k0.52%
Edelweiss Asset Management Ltd.as of 30 Apr 2024273.42k0.48%
Aditya Birla Sun Life Insurance Co. Ltd.as of 30 Apr 202426.72k0.05%
Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 2024134.000.00%
ICICI Prudential Asset Management Co. Ltd.as of 30 Apr 20240.000.00%
More ▼
Data from 29 Feb 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.